Kyverna Therapeutics Initiates First-Ever Rolling BLA for CAR T Therapy in Stiff Person Syndrome, Paving Way for Autoimmune Neurology Revolution
核心洞察
Kyverna Therapeutics initiated a rolling BLA submission in May 2026 for miv-cel (搜索), a CAR T-cell therapy targeting Stiff Person Syndrome (搜索), following positive FDA feedback on a single-arm trial.
This milestone marks the first-ever regulatory filing for an autoimmune CAR T therapy, with a potential market launch anticipated in 2027.
The broader autoimmune neurological disorders market is projected to grow from USD 8.50 billion in 2025 to USD 17.79 billion by 2035, driven by targeted biologics and cell-based therapies.
The autoimmune neurological disorders landscape is on the cusp of a transformative shift as Kyverna Therapeutics initiates the first-ever rolling Biologics License Application (BLA) submission for a chimeric antigen receptor (CAR) T-cell therapy targeting a neurological autoimmune condition. In May 2026, the company began the regulatory filing process for miv-cel (搜索) in the treatment of Stiff Person Syndrome (搜索), following positive feedback from the U.S. Food and Drug Administration on a single-arm clinical trial. This milestone positions Kyverna as the first company to file for an autoimmune CAR T therapy, with hopes of a commercial launch in 2027.
The development represents a potential paradigm shift in the management of autoimmune neurological disorders, moving from lifelong broad immunosuppression toward therapies that promise durable, drug-free remission. Kyverna aims to establish a leading neuroimmunology franchise built on this groundbreaking approach.
A Market Primed for Innovation
The global autoimmune neurological disorders market, valued at USD 8.50 billion in 2025, is projected to reach approximately USD 17.79 billion by 2035, expanding at a compound annual growth rate (CAGR) of 7.90%. This growth is fueled by rising prevalence of conditions such as multiple sclerosis (搜索), neuromyelitis optica spectrum disorder (NMOSD), and myasthenia gravis (搜索), alongside accelerating advancements in targeted biologics and novel delivery systems.
Within this broader market, cell-based therapies are emerging as the fastest-growing treatment segment. According to market analysis, the cell-based therapies segment in neuroimmunology generated approximately USD 1.51 billion in 2025 and is projected to reach nearly USD 6.43 billion by 2035, growing at a remarkable CAGR of 18.5%. This trajectory reflects the increasing research focus on stem cells, regenerative neurology, and immune system reprogramming.
CAR T-Cell Therapy: From Oncology to Autoimmunity
The unprecedented efficacy of CAR T-cell therapies in hematologic malignancies has paved the way for their application in refractory autoimmune conditions affecting the central and peripheral nervous systems. These therapies enable deep immune reprogramming and targeted destruction of autoreactive cells, potentially changing treatment paradigms from chronic management to curative interventions for severe, treatment-refractory neurological diseases.
Germany has emerged as a notable hub for this research direction, with pioneering CAR-T cell therapy programs underway at Uniklinikum Erlangen and Ruhr-University Bochum, shifting focus from merely managing symptoms to curing rare autoimmune neurological conditions.
Recent Regulatory and Research Momentum
The Kyverna milestone is part of a broader wave of innovation in autoimmune neurology. In December 2025, the European Commission approved Johnson & Johnson's IMAAVY (nipocalimab) as a new add-on therapy for generalized myasthenia gravis (搜索). Supported by phase 3 clinical trials, this first-in-class FcRn (搜索) blocker provides adolescents and adults with targeted, long-lasting symptom control by reducing the autoantibodies responsible for the condition.
In April 2026, Alira Health and the Autoimmune Neurology Alliance launched the AXIS Registry to revolutionize autoimmune neurological care, particularly for myasthenia gravis (搜索). The shared platform captures real-world data to optimize treatments, accelerate essential research, and empower patients to actively influence their healthcare journeys.
Meanwhile, in February 2026, researchers from WashU Medicine and the Weizmann Institute of Science engineered CAR-T cells to target amyloid beta plaques in the brain, demonstrating positive results in mice by reducing harmful amyloid plaques and improving overall brain tissue health.
Monoclonal Antibodies Continue to Dominate
Despite the excitement around cell-based therapies, monoclonal antibodies remain the dominant drug class in the autoimmune neurological disorders market, holding a 28% share in 2025 with projected growth at a CAGR of 10.5% through 2035. These highly engineered biologics target specific disease-causing antigens such as CD20 (搜索), CD52, and integrins, halting disease progression while minimizing the adverse effects commonly associated with traditional immunosuppressants.
The multiple sclerosis (搜索) segment continues to represent the largest disease indication, accounting for 35% of the market in 2025, driven by high uptake of expensive monoclonal antibodies, increasing disease prevalence, and a strong pipeline of next-generation regenerative and symptom-management therapies.
The Road Ahead
As Kyverna advances its rolling BLA submission, the autoimmune neurology field watches closely. The success of miv-cel (搜索) could validate CAR T-cell therapy as a viable and potentially curative approach for autoimmune neurological disorders, opening the door for a new class of therapies that offer durable, drug-free remission. With the neuroimmunology market projected to reach USD 91.88 billion by 2035, the convergence of AI-driven drug discovery, precision medicine, and next-generation biologics is reshaping the competitive landscape, rewarding organizations that successfully integrate biologic innovation with advanced research capabilities.